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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) can cause severe infections in patients undergoing haemodialysis. Routine periodic testing
of haemodialysis patients and attempting to decolonize those who test positive may be a strategy to prevent MRSA infections. The economic
value of such a strategy has not yet been estimated. We constructed a Markov computer simulation model to evaluate the economic value
of employing routine testing (agar-based or PCR) at different MRSA prevalence, spontaneous clearance, costs of decolonization and decoloni-
zation success rates, performed every 3, 6 or 12 months. The model showed periodic MRSA surveillance with either test to be cost-effective
(incremental cost-effectiveness ratio £$50 000/quality-adjusted life-year) for all conditions tested. Agar surveillance was dominant (i.e. less
costly and more effective) at an MRSA prevalence ‡10% and a decolonization success rate ‡25% for all decolonization treatment costs tested
with no spontaneous clearance. PCR surveillance was dominant when the MRSA prevalence was ‡20% and decolonization success rate was
‡75% with no spontaneous clearance. Routine periodic testing and decolonization of haemodialysis patients for MRSA may be a cost-effective
strategy over a wide range of MRSA prevalences, decolonization success rates, and testing intervals.
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Introduction
Haemodialysis (HD) patients may be at increased risk
for methicillin-resistant Staphylococcus aureus (MRSA) coloni-
zation and infections [1]. A recent Active Bacterial Core sur-
veillance study found the incidence of invasive MRSA
infections among dialysis patients to be 100-fold that in the
general population [2]. This is not surprising, as HD patients
have a multitude of risk factors, including regular contact
with healthcare facilities, healthcare workers, and invasive
medical devices [3]. Chronic renal failure can lead to immune
system abnormalities and even greater susceptibility to
invasive MRSA infections and poorer outcomes. In fact, infec-
tions are the second leading cause of mortality among
patients with end-stage renal disease [4].
One potential strategy to prevent MRSA infections
among HD patients is routine periodic testing for MRSA
colonization and decolonizing (i.e. the use of antimicrobials
to remove MRSA colonization) patients who test positive.
Whereas some institutions may have implemented this,
others have not, as surveillance programmes can be
costly.
Although a previous study, published in 1996, evaluated
the cost-effectiveness of employing routine screening and
mupirocin decolonization for S. aureus in the dialysis popula-
tion, additional questions and data have emerged over the
last decade [5]. The Bloom et al. study provided important
information but focused on agar-based surveillance, a 1-year
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE EPIDEMIOLOGY
time horizon, one type of vascular access (shunt), shunt
infections (vs. other possible outcomes), and a single decolo-
nization method (mupirocin). The emergence of alternative
testing techniques (i.e. PCR) and decolonization regimens,
such as those involving rifampin and chlorhexidine, raises
questions regarding their role and economic value [6,7]. We
developed a Markov computer simulation model to evaluate
the economic value of routine periodic testing and decoloni-
zation of HD patients for MRSA. Key model parameters
were varied in sensitivity analyses, and allowed us to delin-
eate how the cost-effectiveness of such a strategy may vary
by MRSA prevalence, decolonization cost, and decolonization
success rate. The results of our model may help guide pol-
icy-making and the design of future epidemiological and clini-
cal studies.
Methods
Model structure
Using TreeAge Pro Suite 2009 (TreeAge Software, Williams-
town, MA, USA), we constructed an individual-based Markov
computer model that simulated the decision of whether to test
an HD patient routinely and periodically for MRSA from the
third-party payer perspective. The model evaluated two sur-
veillance methods: a single anterior nares culture (agar-based
surveillance), and nucleic acid detection with an ampliﬁed
probe technique (PCR-based surveillance). Fig. 1a depicts the
ﬂow of the model, which includes ﬁve discrete Markov states:
(i) not MRSA-colonized; (ii) MRSA-colonized without active
infection; (iii) active MRSA infection with outpatient treatment;
(iv) active MRSA infection with inpatient treatment; and (v)
death (absorptive). Each patient entered the model on the
assumption of a three times weekly schedule of dialysis treat-
ment [8]. Each patient entering the model had a probability of
a certain type of access (tunnelled dialysis catheter vs. arterio-
venous ﬁstula vs. arteriovenous graft). At the beginning of each
simulation, the patient had a probability of being already colo-
nized based on the MRSA prevalence. During each cycle, a
non-colonized patient could remain non-colonized or become
colonized, based on MRSA prevalence. A colonized patient
could remain colonized, lose colonization by spontaneous
clearance, develop a clinically apparent MRSA infection and be
medically decolonized, or die. The probability of MRSA coloni-
zation was time-dependent and based on local prevalence. All
probabilities were annual and adjusted for the different cycle
lengths. At the end of each cycle length, modelled as the time
between surveillance intervals, a patient could stay in the same
state or move to another. The MRSA status of each patient
was determined at the end of each cycle, and they transitioned
accordingly. Each patient continued to cycle in the model until
reaching the death state, either from not surviving an infection
or from reaching the end of his or her life-expectancy (median:
4.8 years) [4].
Testing occurred once every cycle (i.e. 3, 6 or
12 months) in the routine testing branch. These chosen
intervals correspond to the timing of other routine tests of
HD patient monitoring, such as adequacy of treatment and
nutritional evaluation [9,10]. Each test had a probability of
identifying MRSA colonization based on its sensitivity.
Patients who tested positive (regardless of their actual col-
onization status) underwent an MRSA decolonization regi-
men, which had a probability of successfully decolonizing
the patient. By contrast, patients who tested negative (even
those who were actually MRSA-colonized) did not receive
MRSA decolonization. Colonized patients could experience
spontaneous clearance of MRSA. All patients with an active
MRSA infection underwent decolonization. In the no-testing
branch, only patients with an active MRSA infection under-
went decolonization. Patients undergoing decolonization
could experience side effects. Successfully decolonized
patients moved to the not MRSA colonized state, whereas
unsuccessful decolonization placed the patients in the
MRSA colonized without active infection state. Successfully
decolonized patients could become recolonized in subse-
quent cycles.
An agar-based test of a clinical isolate identiﬁed infection.
Patients with MRSA infection had probabilities of developing
an invasive infection and receiving inpatient treatment for
any combination of the following conditions: wound infection
(e.g. skin and soft tissue infection), line infection (i.e. infec-
tion of the access site), bacteraemia, endocarditis, pneumo-
nia, and osteomyelitis (Fig. 1b). Those patients requiring
inpatient treatment for these conditions entered the active
MRSA infection with inpatient treatment state. The cost of
hospitalization for each condition came from age-dependent
data from the Healthcare Cost and Utilization Project, and
was based on the mean length of stay for a patient with that
condition. We used length of stay to determine quality-
adjusted life-year (QALY) decrements. The infection attribut-
able costs depended on the type of access; bacteraemia was
associated with access site removal, temporary catheter
insertion, and new access site insertion. All other patients
with active MRSA infection entered the active MRSA infec-
tion with outpatient treatment state.
For each simulation run, we determined the incremental
cost-effectiveness ratio (ICER) of MRSA testing, deﬁned as:
¼ CostMRSA testing  CostNo testing
EffectivenessMRSA testing  EffectivenessNo testing
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where effectiveness is the resulting impact of a given strategy
on a patient’s health, measured in QALYs.
Data inputs
Table 1 shows the probability, cost, QALY and time input
variables for our model. All data came from the published lit-
erature where available, and sources are listed in Table 2.
Probabilities were pulled from triangular or beta distribu-
tions. All costs were converted to 2010 ﬁgures (US$), using
a 3% discount rate, and were either ﬂat values or pulled
from triangular or gamma distributions. All numbers of anti-
microbial administrations were either point values or
assumed a uniform distribution. These numbers were based
on treatment administration at each dialysis event. All dura-
tions of hospitalization represented national medians. The
distribution types chosen depended on available data and the
anticipated bounds of a given parameter. Beta distributions
approximate normal distributions and continuous variables
that are bounded by 0 and 1 [11]. Gamma distributions fre-
quently represent continuous variables that are always posi-
tive and have a skewed distribution, with long upper tails
that represent small fractions of the variability [12]. Triangu-
lar distributions are used when only the lower limit, likeliest
value and upper limit are known. Uniform distributions
depict parameters for which all values within a range have an
equal likelihood. Where multiple sources are listed in
Table 1, the parameter value represents the mean and stan-
dard deviation of all included studies. Expert opinion came
from detailed interviews and consultations with both an
infectious disease physician and a nephrologist.
Each clinical condition resulted in QALY decrements as
listed in Table 1 and that persisted throughout the expected
duration of the clinical condition (also listed in Table 1). Net
QALYs were given by a patient’s age-dependent dialysis
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TABLE 1. Data inputs for variables in our model
Description (units)
Distribution
type Mean
Standard
deviation Range
Source
(Table 2a)
Costs (US$)
Vancomycin, 1-g dose Gamma 10.79 4.73 A
Vancomycin, 500-mg dose Gamma 6.35 3.63 A
Decolonization regimens
Mupirocin, 300-mg dose 15.45 B
Rifampin, twice daily for 10 days 59.56 A
Chlorhexidine, 4% cholorhexidine
gluconate
29.56 A
Death Triangular 6720 (5040–8762) C
Infection outcomes
Bacteraemia (45–64-year-olds) Gamma 13 474.57 716.53 D
Bacteraemia (65–84-year-olds) Gamma 12 983.25 466.79 D
Endocarditis (45–64-year-olds) Gamma 27 637.15 6246.79 D
Endocarditis (65–84-year-olds) Gamma 29 600.74 5405.44 D
Line infection (45–64-year-olds) Gamma 18 740.94 428.43 D
Line infection (65–84-year-olds) Gamma 19 876.59 539.04 D
Osteomyelitis (45–64-year-olds) Gamma 11 048.62 1620.37 D
Osteomyelitis (65–84-year-olds) Gamma 10 495.13 1164.66 D
Pneumonia (45–64-year-olds) Gamma 23 568.24 884.236 D
Pneumonia (65–84-year-olds) Gamma 20 801.53 520.168 D
Wound infection (45–64-year-olds) Gamma 6019.388 655.616 D
Wound infection (65–84-year-olds) Gamma 6590.229 665.627 D
Clinical procedures
Transthoracic echocardiogram Gamma 161.75 44.44 E
Tunnelled dialysis catheter insertion 284.71 E
Tunnelled dialysis catheter removal 140.37 E
Arteriovenous graft insertion 767.88 E
Arteriovenous graft removal 588.18 E
Temporary catheter 121.97 E
Physician consultation Triangular 89.53 (59.09–119.97) E
Agar-based surveillance 12.34 F
PCR-based surveillance 50.27 F
QALY values
Dialysis patients, ages 60–64 years 0.601 G
Dialysis patients, ages 65–84 years 0.549 G
Bacteraemia 0.61 H
Endocarditis 0.615 I
Line infection 0.683 J
Osteomyelitis 0.59 K
Pneumonia 0.87 L
Wound infection 0.683 J
Side effects 0.995 Z
Probabilities
Test characteristics
Sensitivity of agar test Triangular 0.926 (0.63–0.97) M
Speciﬁcity of agar test Triangular 0.971 (0.922–0.995) N
Sensitivity of PCR test Triangular 0.984 (0.91–0.997) O
Speciﬁcity of PCR test Triangular 0.977 (0.956–0.987) O
Access site type
Arteriovenous ﬁstula 0.244 P
Arteriovenous graft 0.051 P
Tunnelled dialysis catheter 0.705 P
MRSA outcomes
Infection if colonized Triangular 0.2692 (0.1777–0.3607) Q
Invasive infection if infected 0.17 R
Inpatient treatment if invasive infection 0.90 R
Clinical conditions of haemodialysis
patient hospitalized for invasive
MRSA infection
Bacteraemia 0.7813 S
Bacteraemia secondary to line infection 0.4706 T
Endocarditis 0.0955 U
Line infection 0.0313 S
Osteomyelitis 0.0625 V
Pneumonia Beta 0.1976 0.0579 W
Wound infection 0.1563 S
Mortality
Mortality, ages 60–64 years 0.174 P
Mortality, ages 65–69 years 0.205 P
Mortality, ages 70–79 years 0.262 P
Mortality from bacteraemia Beta 0.2913 0.0604 X
Mortality from endocarditis Beta 0.4394 0.15 Y
Mortality from pneumonia Beta 0.3053 0.0807 Z
Side effects from treatment 0.57 AA
Number of antimicrobial treatments
Bacteraemia Uniform (12–18) Expert opinion
Endocarditis Uniform (12–18) Expert opinion
Line infection Uniform (6–12) Expert opinion
Osteomyelitis 18 Expert opinion
Pneumonia 6 Expert opinion
Wound infection Uniform (4.29–6) Expert opinion
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QALY (adjusted by cycle length) multiplied by the QALY of
a clinical condition. If patients developed multiple clinical
conditions, they were assigned only the greatest QALY dec-
rement and the maximum cost of treatment and hospitaliza-
tion among their given conditions. Patients had the
probability of side effects from treatment and received
QALY decrements when appropriate. To assess whether the
surveillance strategy was cost-effective, the threshold used in
our model was $50 000/QALY [13]. Our model also
assumed a mean age of 61 years for all dialysis patients [4].
Decolonization regimen scenarios
Separate scenarios examined the use of the following four dif-
ferent decolonization regimens: (i) mupirocin (300 mg) only;
(ii) mupirocin plus rifampin (twice daily for 10 days); (iii) mup-
irocin and rifampin plus chlorhexidine (4% chlorhexidine glu-
conate); and (iv) a regimen costing $200, to determine
whether an even greater cost of treatment would affect our
results. The cost of decolonization varied with treatment regi-
men (Table 1).
Sensitivity analyses
Sensitivity analyses examined the impact of varying the values
of key variables in the model. As the prevalence of MRSA colo-
nization among HD patients is not clearly established and the
efﬁcacies of decolonization methods are unknown, we varied
these parameters over a range of values [1,6,7,14]. We sys-
tematically varied the MRSA prevalence from 0.5% to 20%, the
probability of spontaneous clearance from 0% to 25%, and the
decolonization success rate from 10% to 100%. Each set of
conditions was tested for each decolonization regimen. Cost
of infection was varied from half the baseline costs (Table 1)
to 1.5 times the baseline costs. Testing frequency was simu-
lated for 3-month, 6-month and 12-month periods. For each
simulation run, we conducted probabilistic sensitivity analyses,
which simultaneously varied all input parameters over the
ranges indicated in Table 1.
Results
Each simulation run consisted of 2000 HD patients passing
through the model 2000 times (i.e. 4 000 000 total trials).
Tables 3 and 4 show how the ICER varied with MRSA preva-
lence, decolonization cost, and decolonization success rate,
for agar and PCR testing every 3 months. ‘Dominant’ means
that testing dominated, i.e. was less costly and more effective
than no testing. Routine agar-based surveillance was cost-
effective for all MRSA colonization rates (0.5–20%), decoloni-
zation costs ($15.45–$200), and probabilities of decoloniza-
tion success (10–100%) and spontaneous clearance (0–25%)
at all testing intervals. Testing at 3-month intervals resulted
in ICERs £$1701/QALY (0% spontaneous clearance, decolo-
nization cost $200) and £$1683/QALY (‡25% spontaneous
clearance, decolonization cost $200). For decolonization
costs £$104.57, agar surveillance dominated, with an MRSA
colonization rate ‡5% and a decolonization success rate
‡25%; increasing the cost of decolonization to $200 resulted
in dominance with an MRSA colonization rate ‡10% and the
same decolonization success rate (‡25%). Cost-effectiveness
increased when the frequency of testing was decreased to 6
and 12 months. Agar testing every 6 months resulted in
ICERs £$424/QALY for all decolonization costs and success
rates with a 0% probability of spontaneous clearance. Agar
surveillance remained cost-effective with a 25% spontaneous
clearance probability (ICERs £$434/QALY with decoloni-
zation success ‡25%). Testing dominated the no-testing
strategy for scenarios when MRSA colonization was ‡5%.
Performing agar surveillance every 12 months was even
more cost-effective (ICERs £$114/QALY for all scenarios
tested with no spontaneous clearance, and £$114/QALY for
all scenarios with spontaneous clearance of 25% and a decol-
onization success ‡25%).
Table 4 shows results for PCR surveillance at 3-month
intervals. PCR testing was cost-effective; ICERs were
TABLE 1. Continued
Description (units)
Distribution
type Mean
Standard
deviation Range
Source
(Table 2a)
Duration of hospitalization (days)b
Wound infection 3 D
Line infection 7 D
Bacteraemia 5.5 D
Endocarditis 7 D
Pneumonia 9 D
Osteomyelitis 5 D
MRSA, methicillin-resistant Staphylococcus aureus; QALY, quality-adjusted life-year.
aLetters correspond to the sources in Table 2.
bDuration of hospitalization used for QALY decrements.
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£$4833/QALY for all scenarios evaluated. Performing MRSA
surveillance was the dominant strategy at MRSA prevalence
‡20% and decolonization success rate ‡50% for all decoloni-
zation costs when spontaneous clearance was 0%. Employing
PCR-based surveillance was even more cost-effective when
performed every 6 or 12 months. At a 6-month frequency,
ICERs for PCR surveillance were £$1231/QALY for all sce-
narios evaluated. It became dominant under the same condi-
tions as testing every 3 months. PCR surveillance every
12 months was cost-effective with ICERs £$323/QALY. PCR
testing was dominant at 20% MRSA prevalence and 75%
decolonization success rate when spontaneous clearance
was 0%.
Varying the cost of infection (from 0.5 to 1.5 of base-
line) did not substantially change the results. Surveillance
was still cost-effective for all MRSA colonization rates,
spontaneous clearance rates, and decolonization cost and
success rates. Decreasing the cost of infection resulted in
marginally higher ICERs. Agar surveillance was dominant
with ‡20% MRSA colonization rate and ‡50% decoloniza-
tion success rate when the probability of spontaneous
clearance was 0%. PCR surveillance was dominant with
‡20% MRSA colonization rate and ‡25% decolonization
success rate when the probability of spontaneous clearance
was 0%. Increasing the cost of infection resulted in more
cost-effective ICERs.
TABLE 2. Continued
Z Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with
methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789–1797.
Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: speciﬁc
evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947–955.
DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest
2005; 128: 1414–1422.
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in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest 2008; 133: 363–369.
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TABLE 3. Mean incremental cost-effectiveness ratio (ICER) (95% conﬁdence interval ) of performing routine agar surveillance
at 3-month intervals with varying methicillin-resistant Staphylococcus aureus (MRSA) prevalence and decolonization success
rates with a 0% probability of spontaneous clearance
Probability of MRSA
colonization (%)
Decolonization success (%)
10 25 50 75 100
Decolonization with
mupirocin ($15.45)
0.5 1086
(D, 2958)
1047
(D, 2999)
1027
(D, 2930)
1044
(D, 2920)
1047
(D, 2973)
1 988
(D, 2913)
855
(D, 2673)
818
(D, 2565)
858
(D, 2577)
881
(D, 2628)
2.5 632
(D, 2700)
307
(D, 2086)
305
(D, 2052)
367
(D, 2016)
503
(D, 2274)
Decolonization with mupirocin
and rifampin ($75.01)
0.5 1279
(D, 3189)
1203
(D, 2957)
1170
(D, 3119)
1201
(D, 2992)
1259
(D, 3115)
1 1184
(D, 3204)
1048
(D, 2947)
1036
(D, 2918)
1048
(D, 2862)
1098
(D, 2961)
2.5 898
(D, 2807)
525
(D, 2382)
481
(D, 2171)
564
(D, 2354)
649
(D, 2408)
Decolonization with mupirocin,
rifampin, and chlorhexidine ($104.57)
0.5 1372
(57, 3338)
1297
(D, 3226)
1273
(D, 3278)
1327
(D, 3129)
1309
(40, 3331)
1 1286
(D, 3464)
1147
(D, 2975)
1117
(D, 2876)
1116
(D, 2933)
1178
(D, 3070)
2.5 1039
(D, 3115)
640
(D, 2530)
596
(D, 2497)
665
(D, 2386)
738
(D, 2485)
Bold: surveillance is cost-effective (ICER £$50 000/quality-adjusted life-year).
Dominant (D): surveillance is less costly and more effective than no surveillance.
Results for decolonization cost of $200 are included in the text but not shown in the table.
Results for higher colonization rates (5%, 10%, and 20%) are not shown, as surveillance remains cost-effective.
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Discussion
Our results suggest that routine periodic testing and decolo-
nization of HD patients for MRSA colonization is cost-effec-
tive for a wide range of MRSA prevalence, decolonization
cost and decolonization success rate values. This is consis-
tent with the ﬁndings of Bloom et al. [5] that S. aureus
screening and decolonization of dialysis patients is cost-sav-
ing. Routine agar surveillance had lower ICERs (i.e. had
greater economic value) than PCR, suggesting that the mar-
ginal gains in sensitivity and speciﬁcity afforded by PCR are
outweighed by the increased cost associated with PCR. The
cost of surveillance appears to have a greater impact on the
ultimate economic value of a surveillance strategy than the
cost of the decolonization regimen. Accounting for potential
spontaneous clearance somewhat decreased the economic
value of surveillance but did not substantially change our
results (i.e. active surveillance and decolonization remained
cost-effective throughout all scenarios tested). The choice of
drug regimen (among the available possibilities) also did not
substantially affect the results, suggesting that surveillance
remains cost-effective even when more expensive regimens
are used. MRSA colonization rate was the largest driver of
cost-effectiveness, followed by the probability of successful
decolonization; both increased the cost-effectiveness of sur-
veillance (i.e. lower ICERs). In fact, our results indicate that
employing surveillance becomes economically dominant as
MRSA prevalence increases, even at low decolonization suc-
cess rates. Therefore, when deciding when, whether and
how to implement a surveillance programme, decision-mak-
ers may want to focus on the risk of MRSA colonization and
the efﬁcacy of decolonization. In other words, they may want
to choose the most efﬁcacious decolonization regimen.
Our previous studies have evaluated the economic impact
of routine surveillance and decolonization in vascular surgery,
orthopaedic surgery and cardiac surgery patients, as well as
screening and contact isolation of medical patients in acute-
care hospitals [15–18]. These populations have unique
patient-level risk factors for MRSA that suggest that deci-
sions concerning the implementation of a surveillance pro-
gramme ought to be made for each population. HD patients
have a much higher incidence of invasive MRSA than the gen-
eral population; however, the impact of decolonization in
TABLE 4. Mean incremental cost-effectiveness ratio (ICER) (95% conﬁdence interval) of performing routine PCR surveillance
at 3-month intervals with varying methicillin-resistant Staphylococcus aureus (MRSA) prevalence and decolonization success
rates with a 0% probability of spontaneous clearance
Probability of MRSA colonization (%)
Decolonization success (%)
10 25 50 75 100
Decolonization with mupirocin ($15.45)
0.5 4349
(2343, 7473)
4288
(2324,7239)
4261
(2300, 6978)
4309
(2392, 7516)
4312
(2393, 7237)
1 4204
(2200, 7369)
4058
(2193, 7002)
4079
(2113, 7054)
4109
(2164, 7139)
4204
(2221, 7226)
2.5 3769
(1786, 6710)
3535
(1582, 6456)
3497
(1605, 6199)
3557
(1821, 6317)
3710
(1807, 6639)
5 3166
(1214, 6012)
2654
(826, 5370)
2600
(875, 5220)
2732
(1028, 5159)
2951
(1244, 5390)
Decolonization with mupirocin and
rifampin ($75.01)
0.5 4434
(2440, 7453)
4439
(2389, 7529)
4401
(2369, 7632)
4427
(2364, 7669)
4453
(2445, 7611)
1 4418
(2451, 7417)
4207
(2194, 7270)
4223
(2312, 7166)
4247
(2332, 7369)
4339
(2425, 7395)
2.5 4027
(2031, 6904)
3675
(1720, 6554)
3651
(1730, 6425)
3709
(1811, 6473)
3800
(1979, 6539)
5 3523
(1417, 6822)
2822
(929, 5621)
2744
(1055, 5358)
2907
(1173, 5561)
3066
(1312, 5730)
Decolonization with mupirocin,
rifampin, and chlorhexidine ($104.57)
0.5 4553
(2518, 7572)
4494
(2450, 7576)
4473
(2437, 7455)
4533
(2523, 7612)
4495
(2513, 7433)
1 4478
(2426, 7643)
4335
(2343, 7503)
4285
(2306, 7575)
4310
(2242, 7728)
4409
(2407, 7398)
2.5 4135
(2053, 7598)
3815
(1794, 6923)
3755
(1809, 6887)
3859
(1952, 6833)
3882
(1909, 6944)
5 3665
(1545, 6746)
2927
(1036, 5669)
2791
(974, 5501)
2955
(1216, 5575)
3177
(1294, 5869)
Bold: surveillance is cost-effective (ICER £$50 000/quality-adjusted life-year).
Dominant (D): surveillance is less costly and more effective than no surveillance.
Results for decolonization cost of $200 are included in the text but not shown in the table.
Results for higher colonization rates (5%, 10%, and 20%) are not shown, as surveillance remains cost-effective.
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HD populations may be different from that in surgical popu-
lations, where transient decolonization may decrease the risk
of postoperative infection.
The long-term effectiveness of various decolonization regi-
mens is unclear. Studies have not clearly established the efﬁ-
cacy of decolonization [19]. A double-blind trial of intranasal
mupirocin reported a 25% eradication rate vs. 18% in the
placebo group [20]. A systematic review of decolonization
studies noted that many studies found much higher decoloni-
zation success rates, although variable follow-up times were
used [6]. Short-term decolonization seems to be successful;
however, long-term decolonization is harder to achieve.
Many patients may become recolonized after returning home
or entering other healthcare environments. Moreover, it is
still debated whether decolonization is simply suppression of
colonization for a ﬁnite length of time rather than the indi-
vidual reverting fully to a non-colonized state. Future studies
may clarify the longer-term success rates of different decolo-
nization regimens. However, on the basis of our model, as
long as decolonization is successful in 10% of attempts,
implementing decolonization on MRSA-positive patients
would be cost-effective.
Our study did not consider the possibility that decoloniza-
tion may select for mupirocin resistance. Although several
studies have documented resistance when mupirocin is widely
used in the general population, and with routine mupirocin
use in peritoneal dialysis patients when used both intranasally
and at the exit site, resistance appears to be rare with routine
intranasal application alone in HD patients [7,21].
Our results are conservative with regard to the beneﬁts
of MRSA testing, as our model used the lower end of infec-
tion procedure costs, while excluding rarer MRSA complica-
tions. Our model also did not factor in how testing may
prevent MRSA spread by identifying and either decolonizing
or isolating carriers before they can transmit MRSA to other
patients. Finally, our study did not quantify how information
from routine testing (e.g. MRSA colonization prevalence and
infection incidence) may help public health ofﬁcials, hospital
administrators and researchers to monitor MRSA spread and
the effectiveness of interventions.
Rather than make decisions, computer models provide
information that may help individual nephrologists, HD cen-
tre administrators, hospital infection control personnel and
policy-makers make informed decisions based on their local
circumstances. Models can help elucidate relationships and
factors that are not readily apparent and provide bench-
marks for decision-making. Decision-makers can adapt model
ﬁndings to their unique local circumstances and tailor their
solutions accordingly.
Limitations
All computer simulation models are simpliﬁcations of real life
and cannot completely represent every possible event and
outcome that may result from MRSA colonization or infec-
tion in HD patients. Probabilities were individual-based, and
did not depend on the states of other HD patients. We
selected the more common clinical outcomes for which data
were available. The data inputs for our model came from dif-
ferent studies of varying quality, and may not fully reﬂect the
socio-demographic and clinical heterogeneity of HD patients.
Also, our results may not be generalizable to younger HD
patients, as our model only considered those patients
‡61 years of age.
Conclusions
Our model suggests that routine periodic MRSA testing of
HD patients with either agar-based or PCR-based methods
is cost-effective over a wide range of MRSA prevalence,
decolonization cost and decolonization success rates. Testing
may identify patients at risk for and prevent MRSA infec-
tions, yielding savings that may outweigh the costs of testing
and decolonization. Individual nephrologists, HD centre
administrators, hospital infection control personnel and pol-
icy-makers can compare their local circumstances with the
assumptions and outlined thresholds of our model to make
decisions about whether to implement routine MRSA test-
ing. Future studies could help to delineate MRSA prevalence
and decolonization success rates in different HD popula-
tions.
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